Pharmacovigilance and Related Developments: Industry and Market Analysis 2014-2024
LONDON, April 16, 2014 /PRNewswire/ --
Post-marketing surveillance for medicines - discover trends, outlooks, and revenues
Where are pharmacovigilance and related needs heading? For those pharmaceutical testing studies you get new analysis, also exploring sales predictions. You unlock that medical industry. And you assess its results, trends, technologies, prospects, and opportunities.
Visiongain's updated report forecasts those revenues to 2024 at overall world market, regional, and national level. There stay ahead in data, benefiting your influence. And hear about gains for patients, doctors, healthcare providers, and companies.
Read on, then, to explore assessments of drugs in use, also finding those services' future commercial value.
Analyses exclusive to that study, discussing the most important needs and potentials
Demand rises for those testing, data storage, and monitoring operations. There our study benefits your plans, decisions, and authority by interpreting medical needs, regulations, and companies' efforts. Save time and effort.
And you see what's happening in surveillance of pharmaceuticals, assessing likely challenges, events, and gains. In particular discover prospects for phase IV clinical trials, contract research organisations (CROs), and pharmaceutical companies.
And in those analyses you get data found nowhere else. Our forecasting system goes to the core of sales potentials in those drug safety assessments, showing revenue predictions.
Our report gives 36 tables, 35 charts, and interviews with three companies. There you discover historical results, growth rates, market shares, discussions, and forecasts.
And the following sections show how our new investigation helps you stay ahead.
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
National markets - what outlooks for service demand and provision?
What's the commercial potential of post-marketing studies for medicines? For those testing activities our work forecasts overall world spending to 2024.
Our report also gives you individual forecasts to 2024 for 12 national markets:
• United States (US)
• Japan
• Germany, France, UK, Italy, and Spain (EU5), also with EU regional prediction
• Brazil, Russia, India, and China (BRIC nations), and South Korea.
Stay ahead, then, for information. There you find regions and countries with highest demands, spending, and potential sales growth. Explore progress, needs and opportunities.
Also what events, challenges, and advances in technology affect that industry and market? Our work shows you, discussing progress, policies, and trends influencing that pharma field.
Market forces, events, and issues - developments influencing pharmacovigilance
Find what's happening. Our new report explains issues, processes, and events affecting that industry and market from 2014, including these:
• Reporting systems for adverse drug reactions (ADRs) - their present and future, including data on reported and recorded events by year and region
• Drug approval moving towards post-marketing studies, inc. advances in therapies
• Safety monitoring using reporting from social media - explore possibilities in big data
• Improvements in data collection and communication leading to more-flexible drug approval processes - changing routes of marketing authorisation
• Strengths and weaknesses of procedures and practice in 2014, and how pharma regulatory affairs can progress there to 2024.
And it discusses these trends and influences, among others:
• Policies of national and international bodies, and regulators' roles in present and future pharmacovigilance programmes
• Companies in business process outsourcing (BPO), software providers, regulatory consultants, and contract research organisation (CROs)
• Prediction of overall pharma R&D spending and its effects on that drug monitoring
• Collaboration between the FDA and EMA, and application of pharmacogenomics and biomarkers
• Use of electronic health record (EHR) systems - a live model for drug safety, applying information systems.
There you explore political, economic, social, and technological questions. See too how post-approval R&D lets companies benefit patients. And find what helps and what hinders players in that industry, affecting its results.
So you hear what progress, trends and prospects mean. And you assess what the future holds.
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
Companies and 2018 market value - find commercial potential
What happens next? Our study predicts that overall world market will reach $10.6bn in 2018, with further expansion to 2024.
Also, from 2014, outsourcing of those operations will increase. There pharmaceutical clients, contract research organisations (CROs), and other participants will benefit. See how, discovering potentials.
You examine companies, including these:
• Pfizer
• Johnson & Johnson
• GlaxoSmithKline (GSK)
• Sanofi
• Novartis
• AstraZeneca
• Eli Lilly.
And also these specialist firms:
• Quintiles
• Covance
• Parexel
• Accenture
• Cognizant Technology Solutions
• Infosys
• Oracle.
From this decade, that pharmaceutical testing industry holds many opportunities. And you examine its technological and commercial possibilities, staying ahead in knowledge.
Ways Pharmacovigilance and Related Developments: Industry and Market Analysis 2014-2024 helps
In these four ways, that investigation gives you analysis found only in our work, helping you gain recognition for insight:
• Revenues to 2024 at world level from that spending - assess prospects for investments, marketing, and sales
• Forecasts to 2024 for 12 national markets in the Americas, Europe, and Asia - investigate developed and developing countries for commercial potentials
• Outlooks for established, rising, and emerging product and service providers - explore results, capabilities, news, technologies, activities, and outlooks for success
• Interviews with authorities in the pharmacovigilance industry - scan opinions to help you stay ahead.
Knowledge there found nowhere else, benefiting your searches, analyses, and planning
Our new report gives competitive intelligence, showing where progress, demand, and money exist. Now you explore the pharmacovigilance industry's future through data exclusive to that study.
So our analysis helps you avoid falling behind in information or missing opportunity. Also it lets you save time and effort. And now find how your choice can benefit your plans, decisions, and authority - increasing your chances of gaining advantages.
Trying our new study on post-marketing testing and drug surveillance lets you explore those trends, opportunities, and sales predictions. Stay ahead there - please get that report here now.
To request a report overview please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel : +44 (0) 20 7336 6100
Companies Listed in this report:
Abbott Laboratories
Accenture
Accovion
Actavis
Agence française de sécurité sanitaire des produits de santé
Agencia Española de Medicamentos y Productos Sanitarios
Agenzia Italiana del Farmaco (AIFA)
Aprova
Aptiv Solutions
ARIS Global
AstraZeneca
Bayer
Brazilian Health Surveillance Agency (ANVISA)
Bristol-Myers Squibb
Capgemini
Center for Biologics Evaluation and Research
Center for Drug Evaluation and Research
Central Drugs Standard Control Organization
China Food and Drug Agency
China Food and Drug Agency (CFDA)
Chinese Ministry of Health
Cognizant Technology Solutions
Commission on Human Medicines
Committee for Medicinal Products for Human Use
Committee on the Safety of Medicine
Contergan Foundation
Covance
Crossoak Pharma
Crown Consultants
CSO Pharma Consulting
DADA Consultancy
Danish Medicines Agency
Dose Spot
Drug Safety Alliance
Dun & Bradstreet
Dutch Medicines Evaluation Board
Eli Lilly
Epidemico
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European Medicines Agency (EMA)
European Medicines Evaluation Agency (EMEA)
European Union (EU)
Facebook
Federal Association of Thalidomide Victims
Federal Centre for Monitoring Drug Safety
Federal Institute for Drugs and Medical Devices
Federal Service on Surveillance in Healthcare and Social Development (Roszdravnadzor, Russia)
First Databank
Food and Drug Administration (US FDA)
Foresight Group International
Forest Laboratories
GB Pharma
Geneix
GlaxoSmithKline (GSK)
Handle My Health
Harten Group
HCL Technologies
ICON
iGATE Corporation
Illumina
iMED Global
Imperial Chemical Industries
INC Research
Indian Pharmacopoeia Commission
Infosys
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
inVentiv Health
IPM Safety Services
Japanese Pharmaceuticals and Medical Devices Agency
Johnson & Johnson
Kinapse
Korea Food and Drug Administration
Lindeq
Mahindra Satyam
Medicines and Healthcare Products Regulatory Agency (MHRA, UK)
MedImmune
Merck & Co.
Merck Serono
Ministero della Salute
Ministry of Food and Drug Safety (MFDS, Korea)
Ministry of Health, Labour and Welfare (MHLW, Japan)
National Agency for Safety of Medicine and Health Products
National Patient Safety Agency
NDA Group
Nhumi Technologies
Norwegian Medicines Agency
Novartis
November Research Group
Novo Nordisk
Optum
Oracle
Orbis Clinical
ParagonRX
Parexel
PatientsLikeMe
Patni Computer Systems
Paul Ehrlich Institute
Pfizer
Pharmaceutical and Medical Devices Agency (PMDA, Japan)
Pharmacovigilance Risk Assessment Committee
PharSafer
PPD
PRA International
Primevigilance
Quanticate
Quantum Solutions India
Quintiles Transnational
Ranbaxy
Roche
Sanofi
Sciformix
Serious Adverse Event Consortium (SAEC)
Servier
SGS Life Sciences
Shenyang Pharmaceutical University
State Food and Drug Agency
Sun Pharmaceuticals
Symogen
Synowledge
TAKE Solutions
Tata Consultancy Services
Tech Mahindra
Twitter
UDG Healthcare
uMotif
Unified Health System
United Biosource Company
Uppsala Monitoring Centre (UMC))
Warner Chilcott
Watson
Wipro Limited
Wockhardt
World Bank
World Health Organization (WHO)
Xendo
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
Share this article